Curtis Tatsuoka

Curtis Tatsuoka

Auto-generated profile, based on publicly available information

Curtis Tatsuoka

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2018 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MSMartha M. Sajatovic
Martha M. Sajatovic
KCKari Colon‐Zimmermann
Kari Colon‐Zimmermann
MKMustafa Kahriman
Mustafa Kahriman
EFEdna Fuentes‐Casiano
Edna Fuentes‐Casiano
HLHongyan Liu
Hongyan Liu
PCPeijun Chen
Peijun Chen

30 March 2012 in Journal of Geriatric Psychiatry and Neurology
Verified
Journal Article
Open access
PDF file
AGAriel Gildengers
Ariel Gildengers
CTCurtis Tatsuoka
Curtis Tatsuoka
CBChristopher Bialko
Christopher Bialko
KCKristin A. Cassidy
Kristin A. Cassidy
RJRayan K. Al Jurdi
Rayan K. Al Jurdi
MSMartha M. Sajatovic
Martha M. Sajatovic
Aims: To identify baseline clinical factors associated with acute treatment response in depressed older adults with bipolar disorder (BD) receiving lamotrigine. Methods: Secondary analysis of a multisite, 12-week, open-label, uncontrolled study of add-on lamotrigine in 57 adults 60 years and older with BD I or II depression. Measures included the Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS). Cardiometabolic risk was measured with total serum cholesterol and the Cumulative Illness Rating Scale–Geriatric (CIRS-G) item #13 (endocrine/metabolic burden). Neurocognitive (executive) function was evaluated using the Trail Making Test. Results: Greater reduction in MADRS from baseline was associated with higher baseline cardiometabolic burden at 6 and 9 weeks and lower YMRS scores at 9 weeks. At 12 weeks, improvement in the MADRS from baseline was no longer significantly related to baseline cardiometabolic burden or YMRS scores. A longitudinal mixed model of MADRS scores corroborated these findings with a significant finding of time-by-baseline cholesterol level interaction. In a subset of participants, better baseline executive function was related to greater improvement in the MADRS at 9 weeks but not at 6 or 12 weeks. Among all participants, higher baseline YMRS scores were related to greater likelihood of dropout. Conclusions: Lamotrigine appears to work best in depressed elderly patients with BD who have high cardiometabolic risk and low level of mania. Agents like lamotrigine that act primarily on neuroprogressive pathways involving oxidative stress, neurotrophins, and inflammation may be particularly effective in individuals with BD who have significant cardiometabolic burden because of their effects on shared vulnerability factors in BD and medical illness.

18 December 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TBTimothy F. Burns
Timothy F. Burns
SDSanja Dacic
Sanja Dacic
ACAnish Chakka
Anish Chakka
EMEthan Miller
Ethan Miller
MVMaria A. Velez
Maria A. Velez
LSLaura Stabile
Laura Stabile
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.

3 May 2013 in The Open Cardiovascular Medicine Journal
Verified
Journal Article
Open access
KMKenneth A Mayuga
Kenneth A Mayuga
CGChristopher E Gaw
Christopher E Gaw
CTCurtis Tatsuoka
Curtis Tatsuoka
FFFetnat Fouad-Tarazi
Fetnat Fouad-Tarazi
Objectives: Postural orthostatic tachycardia syndrome (POTS), a heart rate (HR) rise with upright positioning, is dependent on autonomic influences. HR recovery (HR decrease after exercise cessation) is a measure of autonomic function. Characteristics of HR reduction during supine Recovery after head-up Tilt in POTS patients have not been elucidated. Methods: 113 subjects (mean age 41.7 years, 86 female), diagnosed with POTS on head-up Tilt were analyzed. HR’s were recorded during baseline supine position, 70-degree Tilt, and 20 sec, 1 min and 2 min of supine Recovery. Percent HR reduction during Recovery was calculated. Results: Baseline HR was 68.7±13.4 bpm. Maximum HR during Tilt was 109±16.9 bpm. Mean HR was 84.2±20 bpm at 20 sec, 78.5±18.9 bpm at 1-min, and 77.1±18.3 bpm at 2 min of Recovery. Younger age and slower baseline HR were associated with greater HR reductions at 20 sec (p=0.006, p=0.000, respectively). Younger age, slower baseline HR and less time to achieve POTS were associated with greater HR reductions at 1 min (p=0.025, p=0.000, p=0.000, respectively) and at 2 min (p=0.004, p=0.000, p=0.000, respectively). Gender and baseline blood pressures were not significant. Conclusions: In POTS patients, HR quickly decreases upon resuming supine position. Younger age, slower baseline HR and less time to achieve POTS were associated with greater HR reductions during supine Recovery. Further study is needed to determine mechanisms, as well as analyze differences in symptoms or prognosis.

11 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AUAniruddha R. Upadhye
Aniruddha R. Upadhye
CKChaitanya Kolluru
Chaitanya Kolluru
LDLindsey Druschel
Lindsey Druschel
LLLuna Al Lababidi
Luna Al Lababidi
SASami S. Ahmad
Sami S. Ahmad
ASAndrew Shoffstall
Andrew Shoffstall
1 Vagus nerve stimulation (VNS) is FDA approved for stroke rehabilitation, epilepsy, and depression; however, the vagus functional anatomy underlying the implant is poorly understood. We used microCT to quantify fascicular structure and neuroanatomy within human cervical vagus nerves. Fascicles split or merged every ~560 μm (17.8 ± 6.1 events/cm). The high degree of fascicular splitting and merging in humans may explain the clinical heterogeneity in patient responses.

7 February 2014 in The American Journal of Geriatric Psychiatry
Verified
Journal Article
Open access
MSMartha M. Sajatovic
Martha M. Sajatovic
PDPhilipp Dines
Philipp Dines
CTCurtis Tatsuoka
Curtis Tatsuoka
MAMelanie Athey
Melanie Athey
EFEdna Fuentes-Casiano
Edna Fuentes-Casiano
JSJohnny Sams
Johnny Sams